| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention relates to compound of formula: or its pharmaceutically acceptable salts. Values of radicals are as follows: R a represents member, selected from CN, C(O)NR 1 R 2 , C(O)OR 3 ; R 1 and R 2 represent H, R 3 represents H or unsaturated C 1 -C 10 alkyl; X represents member, selected from N, CH and CR b , R b represents member, selected from halogen, substituted or non-substituted C 1 -C 10 alkyl, C(O)OR 4 , OR 4 , NR 4 R 5 , where R 4 and R 5 represent members, independently selected from H, substituted or non-substituted C 1 -C 10 alkyl, substituted or non-substituted C 1 -C 10 heteroalkyl, containing at least 1 heteroatom, where heteroatom represents O or N, and heteroatom can take any internal position in heteroalkyl group or take the position, through which alkyl group is bound to the remaining part of molecule, non-substituted C 3 -C 10 cycloalkyl, pyridyl, substituted with CN group, or independently represents ; and , where alkyl and heteroalkyl substituents are independently selected from the group, including: -R', =O, -CO 2 R', -OR', -OC(O)R', -NR"C(O)R', -NR'R", -CONR'R", pyridyl, halogen, , 4-methylpiperazinyl, 4-methylpiperidinyl, in quantity from 0 to 3; and where R' and R" are independently selected from the group, including hydrogen, non-substituted phenyl, non-substituted C 1 -C 10 alkyl, C 1 -C 10 alkoxy, on condition that R 4 and R 5 , together with atoms to which they are bound, are optionally combined with formation of 4-8-membered non-substituted heterocycloalkyl ring, containing 1-2 heteroatoms, selected from N and O. Also claimed are pharmaceutical compositions, method of treating state, mediated by phosphodiesterase (FDE), a method of FDE inhibition. n EFFECT: invention makes it possible to obtain compounds, capable of inhibiting phosphodiesterase. n 134 cl, 141 dwg, 2 tbl, 29 ex |